| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
73,380,000 |
| Market
Cap: |
1.59(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$16.98 - $26.54 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Schrodinger is engaged in developing a physics-based software platform that enables discovery of molecules for drug development and materials applications. Co.'s software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Co. has two segments: software, which is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries; and drug discovery, which is focused on various portfolio of preclinical and clinical programs, internally and through collaborations, that have developed to various stages of discovery and development.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
22,880 |
30,679 |
32,210 |
61,216 |
| Total Sell Value |
$553,113 |
$759,484 |
$786,710 |
$1,979,107 |
| Total People Sold |
3 |
6 |
7 |
7 |
| Total Sell Transactions |
3 |
8 |
9 |
16 |
| End Date |
2025-03-02 |
2024-11-29 |
2024-05-31 |
2023-06-01 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Aklian Mannix Vartan |
See Remarks |
• – – |
2025-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
14,063 |
14,063 |
|
- |
|
| Jain Rachit |
EVP & CFO |
• – – |
2025-05-21 |
4 |
A |
$0.00 |
$0 |
D/D |
9,375 |
37,097 |
|
- |
|
| Jain Rachit |
EVP & CFOOfficer |
• – – |
2025-05-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
27,722 |
|
-9% |
|
| Akinsanya Karen |
President of R&D, Therapeutics |
• – – |
2025-04-14 |
4 |
AS |
$25.00 |
$419,570 |
D/D |
(16,723) |
15,625 |
|
-19% |
|
| Akinsanya Karen |
President of R&D, Therapeutics |
• – – |
2025-04-14 |
4 |
OE |
$2.92 |
$52,845 |
D/D |
16,723 |
32,348 |
|
- |
|
| Van Kralingen Bridget A |
Director |
– • – |
2025-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
10,000 |
|
- |
|
| Herman Jenny |
SVP & Controller |
• – – |
2025-03-06 |
4 |
AS |
$21.11 |
$14,059 |
D/D |
(666) |
27,349 |
|
3% |
|
| Dugan Margaret |
Chief Medical Officer |
• – – |
2025-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
25,969 |
|
- |
|
| Akinsanya Karen |
President of R&D, Therapeutics |
• – – |
2025-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
15,625 |
15,625 |
|
- |
|
| Lorton Kenneth Patrick |
EVP, CTO & COO, Software |
• – – |
2025-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
53,576 |
|
- |
|
| Herman Jenny |
SVP & Controller |
• – – |
2025-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
9,800 |
28,015 |
|
- |
|
| Farid Ramy |
President & CEO |
• • – |
2025-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
37,500 |
221,932 |
|
- |
|
| Abel Robert Lorne |
See Remarks |
• – – |
2025-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
20,615 |
|
- |
|
| Tran Yvonne |
EVP, CLO & CPO |
• – – |
2025-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
23,635 |
|
- |
|
| Porges Geoffrey Craig |
EVP & CFO |
• – – |
2025-03-03 |
4 |
AS |
$21.76 |
$119,484 |
D/D |
(5,491) |
27,544 |
|
2% |
|
| Porges Geoffrey Craig |
EVP & CFO |
• – – |
2025-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
27,350 |
33,035 |
|
- |
|
| Tran Yvonne |
EVP, CLO & CPO |
• – – |
2025-02-18 |
4 |
AS |
$28.00 |
$109,256 |
D/D |
(3,902) |
11,135 |
|
-17% |
|
| Tran Yvonne |
EVP, CLO & CPO |
• – – |
2025-02-18 |
4 |
OE |
$4.34 |
$16,935 |
D/D |
3,902 |
15,037 |
|
- |
|
| Tran Yvonne |
EVP, CLO & CPO |
• – – |
2025-02-11 |
4 |
AS |
$24.43 |
$20,228 |
D/D |
(828) |
11,135 |
|
-12% |
|
| Lorton Kenneth Patrick |
EVP, CTO & COO, Software |
• – – |
2025-02-11 |
4 |
AS |
$24.43 |
$24,064 |
D/D |
(985) |
41,076 |
|
-12% |
|
| Herman Jenny |
SVP & Controller |
• – – |
2025-02-11 |
4 |
AS |
$24.43 |
$20,985 |
D/D |
(859) |
18,215 |
|
-12% |
|
| Abel Robert Lorne |
See Remarks |
• – – |
2025-02-10 |
4 |
AS |
$25.99 |
$31,838 |
D/D |
(1,225) |
8,115 |
|
-14% |
|
| Dugan Margaret |
Chief Medical Officer |
• – – |
2024-10-15 |
4 |
AS |
$17.78 |
$27,226 |
D/D |
(1,531) |
13,469 |
|
23% |
|
| Lynton Michael |
Director |
– • – |
2024-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
11,250 |
|
- |
|
| Kapeller-Libermann Rosana |
Director |
– • – |
2024-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
11,250 |
|
- |
|
386 Records found
|
|
Page 1 of 16 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.18 (0.84%) 
